ReviewCurrent allergy and asthma reports2024
New insights into chronic inducible urticaria.
Review in Current allergy and asthma reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Update on occupational contact urticaria: a systematic narrative review.Current opinion in allergy and clinical immunology · 2026Pooled it
- Differential Effects of Dupilumab in a Patient With Localized Heat Urticaria, Delayed Solar Urticaria, and Symptomatic Dermographism.The Journal of dermatology · 2026Article
- β-blocker Therapy in Cholinergic Urticaria, Adrenergic Urticaria and the Aquagenic Continuum Beta-Blocker Therapy in Chronic Inducible Urticaria.Clinical reviews in allergy & immunology · 2026Review
- Dupilumab in patients with cold urticaria: Results from a phase 3 trial.The journal of allergy and clinical immunology. Global · 2026Article
- Sexual Dimorphism in Allergic and Mast Cell-Associated Diseases.Clinical reviews in allergy & immunology · 2026Review
- Clinical phenotypes and molecular endotypes of chronic urticaria: Linking clinical expression to underlying immune mechanisms.Asia Pacific allergy · 2026Review
- Advancements and challenges in the management of chronic inducible urticaria.Frontiers in immunology · 2026Review
- Challenges in Differentiating Chronic Inducible Urticaria from Chronic Spontaneous Urticaria.Journal of inflammation research · 2026Review
- Risk Factors for Progression to Chronicity or Recurrent Episodes in Pediatric Acute Urticaria: A 1-Year Cohort Study.Journal of asthma and allergy · 2026Article
- Pathophysiologic Mechanisms and Targeted Treatments Associated with the Nervous System in Cutaneous Allergic Diseases.Clinical reviews in allergy & immunology · 2025Review
- Urticarial Systemic Allergic Dermatitis Following Mitomycin C Instillation.Contact dermatitis · 2025Article
- Cold Urticaria: From Wheals to Anaphylaxis.Allergy, asthma & immunology research · 2025Review
- Contact Urticaria and Related Conditions: Clinical Review.Contact dermatitis · 2025Review
- Exercise-Induced Angioedema, Urticaria, and Anaphylaxis-A Narrative Review.Sports (Basel, Switzerland) · 2025Review
- Beyond the itch: the complex interplay of immune, neurological, and psychological factors in chronic urticaria.Journal of neuroinflammation · 2025Review
- Current treatment practices and efficacy in solar urticaria: insights from a patient survey.Frontiers in immunology · 2025Article
- Key differences between chronic inducible and spontaneous urticaria.Frontiers in allergy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewChronic inducible urticaria (CIndU) is a group of long-persisting and challenging to manage diseases, characterized by recurrent wheals and angioedema induced by definite triggers. In this review, we address recent findings on CIndU pathogenesis, diagnosis as well as its treatment, and we discuss novel potential targets that may lead to the development of more effective therapies for CIndU patients. RECENT ADVANCES: Meaningful advances in the understanding of its pathogenesis have been reported in the last decades. Novel CIndU-specific patient-reported outcome measures enable a closer and better evaluation of patients. CIndU is a hard-to-treat disease that highly impairs quality of life (QoL) of affected patients. Provocation tests allow to diagnose CIndU subtypes. The only licensed and recommended treatment for CIndU are second generation non-sedating H1-antihistamines, which lack efficacy in many cases. Omalizumab off-label use has been assessed in all types of CIndU with overall good outcomes. Promising emerging therapies currently assessed in chronic spontaneous urticaria are paving the path for novel treatments for CIndU.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.